Roni Shouval
Overview
Explore the profile of Roni Shouval including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beyar-Katz O, Rejeski K, Shouval R
Haematologica
. 2025 Feb;
PMID: 39973361
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematologic malignancies. However, it is frequently complicated by immune effector cell-associated hematotoxicity (ICAHT), a potentially life-threatening adverse event...
2.
Samples L, Sadrzadeh H, Frigault M, Jacobson C, Hamadani M, Gurumurthi A, et al.
Blood
. 2025 Feb;
PMID: 39938007
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 CAR T-cell therapy outcomes in patients...
3.
Corona M, Ip A, Brown S, Luna A, Khatib H, Flynn J, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39893244
CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has recently been approved as second-line treatment for relapsed/refractory large B-cell lymphoma (LBCL). This study compares patterns of disease relapse and progression across...
4.
Tumuluru S, Godfrey J, Cooper A, Yu J, Chen X, MacNabb B, et al.
Blood
. 2025 Jan;
PMID: 39869833
Most diffuse large B-cell lymphoma (DLBCL) patients treated with immunotherapies such as bispecific antibodies (BsAb) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the...
5.
Sdayoor I, Shouval R, Fried S, Marcus R, Danylesko I, Yerushalmi R, et al.
Blood Adv
. 2025 Jan;
PMID: 39774788
Pulmonary function tests (PFT) are recommended for hematopoietic cell transplantation (HCT) evaluation. However, their prognostic value in chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We assessed the predictive significance...
6.
Luan D, DeWolf S, Fei T, Raj S, Shah G, Lareau C, et al.
Blood Cancer Discov
. 2024 Dec;
6(2):119-130.
PMID: 39666878
This study reveals differences in IR patterns after CAR-T therapy in patients with large B-cell lymphoma, with early NK cell recovery emerging as a key predictor of survival. These findings...
7.
Boardman A, Gutgarts V, Flynn J, Devlin S, Goldman A, Tomas A, et al.
Haematologica
. 2024 Nov;
110(3):651-664.
PMID: 39568416
Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable remissions in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), but many patients experience treatment-related toxicity. Cytokine release syndrome and...
8.
Nair M, Silbert S, Rejeski K, Wilson K, Lamble A, Lamble A, et al.
Blood
. 2024 Nov;
145(11):1136-1148.
PMID: 39561284
Immune effector cell-associated hematotoxicity (ICAHT) is a major B-cell targeted chimeric antigen receptor (CAR) T-cell related toxicity. Although ICAHT incidence and severity is documented in large B-cell lymphoma (LBCL), mantle...
9.
Liang E, Rejeski K, Fei T, Albittar A, Huang J, Portuguese A, et al.
Bone Marrow Transplant
. 2024 Nov;
60(2):254.
PMID: 39533017
No abstract available.
10.
Fei T, Funnell T, Waters N, Raj S, Baichoo M, Sadeghi K, et al.
Cell Rep Methods
. 2024 Nov;
4(11):100899.
PMID: 39515336
Identifying predictive biomarkers of patient outcomes from high-throughput microbiome data is of high interest, while existing computational methods do not satisfactorily account for complex survival endpoints, longitudinal samples, and taxa-specific...